PSA Enters into Business Alliance Agreement with NeoGenomics Laboratories
Florence, SC – Pathology Service Associates, LLC (PSA), a MED3OOO Company, the country’s leading provider of revenue cycle management and other business support services to independent pathologists across the United States, has entered into a Business Alliance Agreement with NeoGenomics Laboratories,Inc.
PSA’s Business Alliance Program enables PSA-affiliated practices to purchase pathology equipment, supplies, and services at discounted rates negotiated by PSA. NeoGenomic’s commitment to the Business Alliance Program will provide PSA’s affiliated physicians with savings on testing in cancer genetics, flow cytometry, immunohistochemistry and molecular diagnostics. NeoGenomics Laboratories, Inc. is one of the nation’s premier cancer-specific, high complexity reference laboratories. Led by internationally recognized genetics experts, NeoGenomics’ mission is to support pathologists with industry leading turn-around times, unparalleled service, and complete dedication to the needs of clients and patients alike.
“We are very pleased to add NeoGenomics to our select vendor list,” said Randal Sanderson, PSA Vice President of Business Development. “The scope of products, services and value offered through the alliance with NeoGenomics should enable a broad cross-section of practices to have access to industry leading cancer genetic services while recognizing meaningful savings. PSA’s Business Alliance Program has long been an important underpinning of the practice support services PSA offers pathologists. Our mission is to support independent community-based pathology groups, and providing this type of program enables all of our affiliated physicians to level the playing field in terms of negotiating pricing and terms for laboratory supplies, equipment, and services.”
“We share PSA’s excitement about this new strategic alliance” added Grant Carlson, VP of Sales Marketing at NeoGenomics. “We are pleased by the increasing number of pathology practices across the country that are now turning to NeoGenomics for our full menu of specialized cancer genetic pathology services. There has been an especially heightened interest in our newer and proprietary service offerings, including our FISH probes for hematopoietic diseases and MelanoSITE, our exclusive 4-probe FISH assay to help improve classification of melanocytic neoplasms with conflicting morphologic criteria. This alliance with PSA allows NeoGenomics another opportunity to expand upon our commitment to provide world-class cancer-specific services to PSA-affiliated pathology practices.”